medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2024, Number 08

<< Back Next >>

Ginecol Obstet Mex 2024; 92 (08)

Association between the degree of alcohol, tobacco, illicit of alcohol, tobacco, illicit substances and adverse obstetric outcome

Palomo GM, Álvarez VNA, Feria SAL

Language: Spanish
References: 16
Page: 326-340
PDF size: 235.39 Kb.


ABSTRACT

Objective: To determine the relationship between the extent of alcohol, tobacco and illicit substance use and adverse obstetric outcomes to enable obstetric care providers to assess the risks of substance use.
Materials and Methods: Retrospective, observational, analytical and crosssectional study of a case series of postpartum patients who were admitted to the Gynaecology and Obstetrics Service of the General Hospital of Saltillo between March and June 2023 and who reported alcohol, tobacco or drug use during pregnancy. After the obstetric procedure, the ASSIST tool or screening test for alcohol, tobacco and drug use was applied. Pearson's χ2 test and Fisher´s exact statistic were used to assess their association with adverse outcomes according to the level of use.
Results: Of 863 obstetric attendances, 47 patients (5.4%) reported active use of different substances during pregnancy; of these, 22 used 2 substances, with a trend between tobacco and cannabis use for adverse obstetric outcomes (p = 0.16 and 0.17, respectively). The most common adverse obstetric outcome was low birth weight in 22 of 47 patients.
Conclusions: The substances with the highest tendency for adverse obstetric outcome were tobacco and cannabis, and the most common adverse neonatal outcome was low birthweight.


REFERENCES

  1. Barry JM, Birnbaum AK, Jasin LR, Sherwin CM. Maternalexposure and neonatal effects of drugs of abuse. J ClinPharmacol 2021; 61: S142-S155. https://doi.org/10.1002/jcph.1928

  2. England LJ, Bennett C, Denny CH, et al. Alcohol use andco-use of other substances among pregnant females aged12-44 Years -United States, 2015-2018. MMWR 2020; 69:1009-14. https://www.cdc.gov/mmwr/volumes/69/wr/mm6931a1.htm

  3. Ko JY, Coy KC, Haight SC, et al. Characteristics of marijuanause during pregnancy -eight states, Pregnancy Risk AssessmentMonitoring System. MMWR Morb Mortal WklyRep 2020; 69 (32): 1058-63. https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6932a2-H.pdf

  4. Li JH, Liu JL, Zhang KK, et al. The adverse effects of prenatalMETH exposure on the offspring: A Review. Front Pharmacol2021; 12: 715176. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317262/

  5. Etemadi-Aleagha A, Akhgari M. Psychotropic drug abusein pregnancy and its impact on child neurodevelopment:A review. World J Clin Pediatr 2022; 11 (1): 1-13. https://doi.org/10.5409/wjcp.v11.i1.1

  6. Rojo MG, Jiménez PM, Ochoa IZ, et al. Perfil sociodemográficode madres embarazadas consumidoras de drogasilegales atendidas en un Hospital Materno Infantil. Rev SalJal 2021; 8. (3): 160-167. https://ssj.jalisco.gob.mx/sites/ssj.jalisco.gob.mx/files/revista_saludjalisco_no_24_0.pdf#page=10

  7. Chiandetti A, Hernandez G, Mercadal-Hally M, et al.Prevalence of prenatal exposure to substances of abuse:questionnaire versus biomarkers. Reprod Health 2017;14 (1): 137. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657059/pdf/12978_2017_Article_385.pdf

  8. World Health Organization (WHO) Library Cataloguingin-Publication Data. Guidelines for the identification andmanagement of substance use and substance use disordersin pregnancy. 2014. Switzerland. https://iris.who.int/bitstream/handle/10665/107130/9786162715266-tha.pdf

  9. Organización Mundial de la Salud. La prueba de detecciónde consumo de alcohol, tabaco y sustancias (ASSIST).Manual para uso en la atención primaria. 2011. https://www3.paho.org/hq/dmdocuments/2011/consumosustancias-Assist-manual.pdf

  10. Coleman-Cowger VH, Oga EA, Peters EN, Trocin K, et al.Comparison and validation of screening tools for substanceuse in pregnancy: a cross-sectional study conducted inMaryland prenatal clinics. BMJ 2018; 8 (2): e020248.https://doi.org/10.1136/bmjopen-2017-020248

  11. Coleman-Cowger VH, Oga EA, Peters EN, et al. Accuracy ofthree screening tools for prenatal substance use. Obstetricsand Gynecology 2019; 133 (5): 952-61. https://doi.org/10.1097/AOG.0000000000003230

  12. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure tocannabis and maternal and child health outcomes: a systematicreview and meta-analysis. BMJ Open 2016; 6 (4):e009986. https://doi.org/10.1136/bmjopen-2015-009986

  13. Hacker M, Firk C, Konrad K, et al. Pregnancy complications,substance abuse, and prenatal care predict birthweightin adolescent mothers. Arch Public Health 2021;79: 137. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320202/

  14. Gómez-Ruiz LM, Marchei E, Rotolo MC, et al. Prevalenceof licit and illicit drugs use during pregnancy in mexicanwomen. Pharmaceuticals 2022; 15: 382. https://doi.org/10.3390/ph15030382

  15. NORMA Oficial Mexicana NOM-007-SSA2-2016, Para laatención de la mujer durante el embarazo, parto y puerperio,y de la persona recién nacida. https://www.dof.gob.mx/nota_detalle.php?codigo=5432289&fecha=07/04/2016#gsc.tab=0

  16. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz;Instituto Nacional de Salud Pública, Comisión NacionalContra las Adicciones. Encuesta Nacional de Consumo deDrogas, Alcohol y Tabaco 2016-2017: Reporte de Drogas. 1ªed. Ciudad de México: Secretaría de Salud. 2017. https://drive.google.com/file/d/1zIPBiYB3625GBGIW5BX0TT_YQN73eWhR/view,




2020     |     www.medigraphic.com